XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]          
Accounts receivable, Allowance for credit loss $ 0   $ 0   $ 0
Accounts receivable, Allowance for credit loss writeoff     0 $ 0  
Research and development costs 90,419 $ 127,228 195,619 $ 286,918  
Deferred offering costs 254,852   $ 254,852    
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]          
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]          
Concentration risk, percentage     67.00%    
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Five Customers [Member]          
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]          
Concentration risk, percentage         73.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Two Customers [Member]          
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]          
Concentration risk, percentage     47.00% 47.00%  
Selling and Marketing Expense [Member]          
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]          
Advertising expense $ 16,000 $ 65,000 $ 32,000 $ 130,000